How Investors Are Reacting To Palo Alto Networks (PANW) Raising Guidance Despite a GAAP Loss
Palo Alto Networks, Inc. PANW | 0.00 |
- Palo Alto Networks reported its fiscal 2026 third-quarter results on 2 June, with revenue rising to US$3.00 billion from US$2.29 billion a year earlier, while swinging from net income of US$262.00 million to a net loss of US$177.00 million.
- Alongside raising full-year revenue guidance and highlighting rapid uptake of AI security platforms like Prisma AIRS, the company’s growing reliance on acquisitions and high stock-based compensation has sharpened investor focus on the quality and profitability of this expansion.
- With management lifting guidance yet posting a GAAP loss, we’ll examine how this tension between growth and profitability reshapes Palo Alto Networks’ investment narrative.
This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
Palo Alto Networks Investment Narrative Recap
To stay invested in Palo Alto Networks, you need to believe its shift from a firewall vendor to an AI‑first security platform can support durable, high‑quality growth despite rising costs. The latest results reinforce the core growth story with strong revenue and raised guidance, but the swing to a GAAP loss and heavy stock‑based compensation keep profitability and dilution as the key near‑term risk, and this tension does materially shape how the stock’s current valuation is viewed.
Against this backdrop, the upgraded full‑year FY2026 guidance to US$11.415 billion to US$11.425 billion in revenue is particularly relevant. It underlines management’s confidence that demand for newer platforms such as Prisma AIRS and Cortex can support higher top‑line expectations even as integration spending, acquisitions and infrastructure costs pressure margins. Whether this upgraded outlook proves sustainable is likely to be central to how investors weigh growth against the risks tied to acquisitions and profitability.
Yet even with strong revenue guidance, the recent GAAP loss, high stock‑based pay and ongoing acquisition integration are risks investors should be aware of...
Palo Alto Networks' narrative projects $16.8 billion revenue and $2.4 billion earnings by 2029. This requires 19.4% yearly revenue growth and about a $1.1 billion earnings increase from $1.3 billion today.
Uncover how Palo Alto Networks' forecasts yield a $300.56 fair value, a 7% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming revenue could reach about US$17.3 billion and earnings US$3.5 billion by 2029, so compared with the recent GAAP loss and margin pressure, you can see how views on AI‑driven growth and acquisition execution can differ sharply and why it is worth comparing several narratives before deciding what you believe.
Explore 19 other fair value estimates on Palo Alto Networks - why the stock might be worth as much as 7% more than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Palo Alto Networks research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
- Our free Palo Alto Networks research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Palo Alto Networks' overall financial health at a glance.
Want Some Alternatives?
Our top stock finds are flying under the radar-for now. Get in early:
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
